Kindly MD (NAKA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 30.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 4.56
• Revenue Growth: -31.13%
• EPS Growth: -126.02%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 439,850,900
• 10 Day Avg. Volume: 32,220,503
• 30 Day Avg. Volume: 30,978,537
• PEG Ratio: -0.01
• Price to Book (P/B): 2.60
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -2.17
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 1.53
• Enterprise Value/Gross Profit: 1.55
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: $1.25
• Price Target Upside: 171.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $0.50 ▲(8.70% Upside)

The overall stock score of 38 reflects significant financial and technical challenges. The company's financial performance is weak, with declining revenues and profitability issues. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively contribute to a low stock score.

Positive Factors

High Gross Profit Margin

A high gross profit margin indicates efficient cost management in production, suggesting potential for profitability improvement if revenue growth is achieved.

Moderate Debt Level

Moderate leverage allows financial flexibility and reduces risk, enabling the company to potentially invest in growth opportunities without excessive financial strain.

Equity Ratio Improvement

Improved equity ratio suggests better asset financing through equity, enhancing financial stability and reducing dependency on debt financing.

Negative Factors

Negative Revenue Growth

Declining revenue growth indicates challenges in market demand or competitive positioning, potentially impacting long-term financial health and market share.

Negative Profit Margins

Substantial losses reflected in negative profit margins highlight operational inefficiencies, requiring strategic cost management and revenue enhancement efforts.

Cash Flow Struggles

Negative cash flow indicates challenges in generating sufficient cash from operations, potentially limiting the company's ability to fund growth and meet financial obligations.

Kindly MD Business Overview & Revenue Model

Company Description

Kindly MD, Inc., a healthcare and healthcare data company, provides direct health care services to patients integrating prescription medicine and behavioral health services. The company offers specialty outpatient clinical services based on a subscription and fee-for-service basis to augment traditional healthcare. It provides evaluation and management services, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, overdose education, peer support, limited urgent care, preventative medicine, travel, and hormone therapy; and data collection and research, and online and email campaign marketing services, as well as engages in the retail sale of health care products through clinics and online. Kindly MD, Inc. was formerly known as Utah Therapeutic Health Center, LLC and changed its name to Kindly MD, Inc. in March 2022. The company was incorporated in 2019 and is based in Salt Lake City, Utah.

How the Company Makes Money

Kindly MD generates revenue primarily through a subscription-based model, where patients pay a monthly fee for access to telehealth services and personal health management tools. Additionally, the company earns income from fee-for-service consultations, where patients are charged per visit with healthcare professionals. Strategic partnerships with insurance companies and healthcare organizations also contribute to revenue, as these partnerships often facilitate bundled services or reimbursements for virtual care. Furthermore, Kindly MD may explore additional revenue streams through the sale of health-related products and wellness programs integrated into their platform.

Kindly MD Financial Statement Overview

Summary

Kindly MD, Inc. is facing significant financial challenges, with declining revenues and profitability issues. Although the balance sheet shows some stability with a moderate debt level, negative equity in 2023 and reliance on financing raise concerns. Cash flow struggles highlight the need for better operational efficiency and cost management to improve financial health.

Income Statement

Kindly MD, Inc. has faced significant challenges in revenue and profit growth. The Gross Profit Margin remains high at 96.95% for 2024, but the Net Profit Margin is negative at -133.00%, indicating substantial losses. The company has faced revenue decline from the previous year, further exacerbating its profitability issues. The negative EBIT and EBITDA margins highlight operational inefficiencies and the need for cost management.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.31, indicating a moderate level of leverage. However, the negative equity in 2023 raises concerns about financial stability. The Return on Equity is not meaningful due to negative equity in 2023, but the Equity Ratio improved to 69.82% in 2024, reflecting better asset financing through equity.

Cash Flow

Cash flow analysis shows a negative Free Cash Flow of -$3.09 million in 2024, indicating cash management struggles. The Operating Cash Flow to Net Income Ratio is negative, reflecting inefficiencies in converting income into cash. The company heavily relies on financing activities to support its cash needs, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.98M	2.72M	3.77M	3.79M	2.50M
Gross Profit	1.96M	2.64M	-264.17K	-595.29K	914.92K
EBITDA	-89.61M	-3.00M	-1.36M	-2.42M	124.74K
Net Income	-90.49M	-3.62M	-1.62M	-2.54M	149.34K
Balance Sheet
Total Assets	692.42M	3.68M	1.10M	947.00K	447.64K
Cash, Cash Equivalents and Short-Term Investments	24.19M	2.27M	525.50K	186.92K	94.69K
Total Debt	203.54M	783.68K	636.38K	391.13K	109.81K
Total Liabilities	214.86M	1.11M	1.21M	565.98K	174.56K
Stockholders Equity	477.56M	2.57M	-108.41K	381.01K	273.09K
Cash Flow
Free Cash Flow	-19.75M	-3.48M	-463.91K	-457.77K	57.84K
Operating Cash Flow	-16.85M	-3.07M	-449.49K	-140.38K	121.44K
Investing Cash Flow	-686.69M	-401.63K	-14.42K	-317.39K	-63.60K
Financing Cash Flow	724.08M	5.22M	802.49K	550.00K	-45.34K

Kindly MD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAKA, the sentiment is Positive. The current price of 0.46 is above the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.52, and below the 200-day MA of 5.88, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.07 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAKA.

Kindly MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SILA	67 Neutral	$1.29B	33.03	2.77%	6.98%	3.74%	77.82%
INBX	62 Neutral	$1.06B	-7.42	-144.07%	―	―	―
EYPT	58 Neutral	$1.34B	-5.33	-98.23%	―	-7.38%	-49.03%
RAPP	56 Neutral	$1.38B	-10.03	-23.41%	―	―	-37.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBNX	50 Neutral	$886.66M	-9.85	-47.52%	―	67.01%	-39.19%
NAKA	38 Underperform	―	-0.41	-81.92%	―	-31.13%	-126.02%

Kindly MD Corporate Events

KindlyMD Authorizes $10 Million Share Repurchase Program

On December 17, 2025, KindlyMD held its annual stockholders’ meeting virtually, with approximately 60.84% of outstanding shares represented, and shareholders elected two Class I directors for three-year terms, approved the company’s conversion from a Utah to a Delaware corporation, ratified Sadler, Gibb & Associates, LLC as independent auditor for fiscal 2025, and authorized potential adjournment of the meeting if additional votes were needed. On December 18, 2025, the board approved a share repurchase program of up to $10 million of common stock and entered into a Rule 10b-18 repurchase plan with TD Securities Inc., a move intended to enhance capital allocation flexibility and signaling management’s confidence in the company’s long-term value and Bitcoin-focused treasury strategy, with potential implications for shareholder returns and capital structure.

The most recent analyst rating on (NAKA) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.

Kindly MD Faces Nasdaq Non-Compliance Notice

On December 10, 2025, Kindly MD, Inc. received a notice from Nasdaq indicating non-compliance with the listing rule due to its stock price falling below $1.00 per share for 30 consecutive days. The company has until June 8, 2026, to regain compliance by ensuring its stock price closes at or above $1.00 for at least 10 consecutive days. If unable to comply, Kindly MD may transfer to the Nasdaq Capital Market, subject to certain conditions, to avoid delisting.

The most recent analyst rating on (NAKA) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.

Kindly MD Appoints New CFO and CAO

On December 8, 2025, KindlyMD, Inc. announced the appointments of Teri Gendron as Chief Financial Officer and John Dalton as Chief Accounting Officer. Both executives bring extensive experience in finance and accounting, which is expected to support KindlyMD’s growth and its Bitcoin treasury strategy. Gendron, previously with Markel Group Inc. and Jefferies Financial Group, will also serve as Treasurer, while Dalton, formerly with Jefferies Finance LLC, will enhance the company’s financial architecture. These appointments aim to strengthen KindlyMD’s financial and operational foundation, ensuring disciplined scaling and value delivery for shareholders.

The most recent analyst rating on (NAKA) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Kindly MD stock, see the NAKA Stock Forecast page.